Lipid–calcium phosphate nanoparticles for delivery to the lymphatic system and SPECT/CT imaging of lymph node metastases by Tseng, Yu Cheng et al.
Lipid-Calcium Phosphate Nanoparticles for Delivery to the
Lymphatic System and SPECT/CT Imaging of Lymph Node
Metastases
Yu-Cheng Tseng1, Zhenghong Xu1, Kevin Guley2, Hong Yuan2, and Leaf Huang1,*
1Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman
School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7571,
USA
2Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill,
NC 27599-7571, USA
Abstract
A lipid/calcium/phosphate (LCP) nanoparticle (NP) formulation (particle diameter ~25 nm) with
superior siRNA delivery efficiency was developed and reported previously. Here, we describe the
successful formulation of 111In into LCP for SPECT/CT imaging. Imaging and biodistribution
studies showed that, polyethylene glycol grafted 111In-LCP preferentially accumulated in the
lymph nodes at ~70% ID/g in both C57BL/6 and nude mice when the improved surface coating
method was used. Both the liver and spleen accumulated only ~25% ID/g. Larger LCP (diameter
~67 nm) was less lymphotropic. These results indicate that 25 nm LCP was able to penetrate into
tissues, enter the lymphatic system, and accumulate in the lymph nodes via lymphatic drainage
due to 1) small size, 2) a well-PEGylated lipid surface, and 3) a slightly negative surface charge.
The capability of intravenously injected 111In-LCP to visualize an enlarged, tumor-loaded sentinel
lymph node was demonstrated using a 4T1 breast cancer lymph node metastasis model. Systemic
gene delivery to the lymph nodes after IV injection was demonstrated by the expression of red
fluorescent protein cDNA. The potential of using LCP for lymphatic drug delivery is discussed.
1. Introduction
The lymphatic system is a central component of the immune system and serves as the
secondary circulation system responsible for the drainage of fluid, proteins, and waste
products from tissues into the blood. Lymph nodes also play an important role in infectious
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disease, inflammation, and cancer [1]. Primary tumors commonly invade draining lymph
nodes, which then serve as a reservoir for further metastatic spread of cancer cells [2–4].
The delivery of genes and drugs to both local, draining lymph nodes and the lymphatic
system as a whole is a challenging task. Certain lipophilic compounds such as long-chain
fatty acids, cholesterol esters, triglycerides, and lipid-soluble vitamins can be transported
through the lymphatic channels [1, 5]. However, most chemotherapy agents do not gain
access to the lymphatic system and lymph node metastases after conventional intravenous
(IV) infusion [1, 5]. Consequently, the development of clinical chemotherapy for lymph
node metastasis has remained elusive.
Many different types of nanoparticle (NP), including liposomes, silica NPs, and other
polymer-based drug delivery systems, have exhibited improved efficiency in regionally
delivering drugs to the lymphatic system [6–10]. For example, intraperitoneally (IP) injected
liposomes containing doxorubicin result in an 8- to 14-fold (4 h post injection) and a 3- to 6-
fold (24 h post injection) increase in doxorubicin concentration in the draining lymph nodes
in rats compared to free doxorubicin [6]. However, no significant difference was observed
after IV administration. Thus, methods for effective delivery of IV administered NP to the
lymphatic system are still needed for the detection of lymph node metastasis.
Non-invasive imaging techniques using nuclear medicine, such as single photon emission
computer tomography (SPECT) and positron emission tomography (PET) have been
developed [11, 12]. Among the radionuclides used in clinical practice, 111In is the second
most widely used radionuclide in clinical practice, surpassed only by 99mTc. 111In displays
major decay at photon energy levels of 171.3 and 245.4 keV, within the ideal range of the
detector device. The half-life of 111In (2.83 days) is also advantageous because prolonged
exposure to the radionuclide may cause undesired toxicity and should be prevented. Many
studies have demonstrated in vivo imaging of tumors with various types of NPs using
SPECT/CT or PET/CT technique [12–14].
Lipid/calcium/phosphate (LCP) NPs were first developed for siRNA delivery [15–17] and
can also successfully deliver plasmid DNA to hepatocytes [18]. Based on the mechanism of
formation of the CaP core, we hypothesized that any drug or radionuclide that can form co-
precipitates with CaP has the potential to be formulated into LCP. Since indium (In) can
form precipitates with phosphate very efficiently (solubility product constant, Ksp, of InPO4
= 2.3×10−22) in a manner similar to that of calcium (Ksp of Ca3(PO4)2 = 1.0×10−25), we
hypothesize that 111In will be a good candidate to add to LCP formulations to provide in
vivo imaging capability.
Systemic accumulation of NPs in the lymph nodes after IV administration has rarely been
reported. A 25 nm, dextran-coated, ultrasmall super-paramagnetic iron oxide (USPIO,
Feridex®) NP has shown systemic lymphotropism after IV administration and has been
evaluated for MRI of clinical lymph node metastasis [19–22]. However, larger iron oxide
NPs coated with the same dextran coating were found to preferentially accumulate in the
liver and spleen [19]. Another self-luminescing, near-infrared semiconductor polymer NP
(30~40 nm) capable of accumulating in the lymph node at a certain level has been described
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recently for lymph node mapping and tumor imaging [23]. However, quantitative data
showing the level of accumulation is missing and liver showed the highest accumulation
according to near-infrared fluorescent imaging.
Other NPs of similar size (25~30 nm) or smaller may exhibit prolonged circulation time in
the blood. No preferential accumulation in lymph nodes has been reported, however. For
example, one recent publication reported that PET imaging demonstrated a long-circulating,
15 nm, micellar NP had minimal accumulation in the liver and spleen, with ~6% ID/g tumor
accumulation. However, this micellar NP did not show lymphotropism [24]. Another recent
publication reported 30 nm Au nanocages for use in tumor PET imaging also exhibit
minimal accumulation in the liver and spleen but no lymphotropism [25]. Thus, NP
lymphotropism may be correlated not only with NP size but also other surface properties.
In this paper, we demonstrate that LCP were able to achieve both systemic delivery of genes
to the lymphatic system and imaging of lymph node metastasis by a mechanism similar to
the aforementioned Feridex®. The systemic lymphotropism of LCP and Feridex® was
achieved by tissue penetration and an atypical lymphatic drainage mechanism that is
different from phagocytic uptake mechanisms used by locally injected NPs to accumulate at
regional draining lymph nodes. Coating of the NP surface with a lipid bilayer or dextran
may contribute to the unusual lymphotropism.
2. Materials and Methods
2.1 Materials
Cholesterol, 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), dioleoylphosphatydic acid
(DOPA), 1,2-Dioleoyl-3-trimethylammonium-propane chloride salt (DOTAP), 1,2-
distearoryl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol-2000)
ammonium salt (DSPE-PEG2000), and 1-oleoyl-2-[12-[(7-nitro-2-1,3-benzoxadiazol-4-
yl)amino] dodecanoyl]-sn-glycero-3-phosphocholine (NBD-PC) were purchased from
Avanti Polar Lipids, Inc. (Alabaster, AL). 111InCl in 0.05 N HCl was purchased from
PerkinElmer (Waltham, MA). Double-strand oligo DNA (sense sequence, 5′-
CAAGGGACTGGAAGGCTGGG-3′) and Texas-Red labeled sense-strand oligo DNA
(sequence: 5′-[TxRd]CAAGGGACTGGAAGGCTGGG-3′) were both synthesized by
Sigma-Aldrich (St. Louis, MO). 3H labeling of oligonucleotides was prepared by hydrogen
exchange with 3H2O at the C8 positions of the purines [26]. 4T1-luc2-GFP Bioware® Ultra
Green) cell line was purchased from Caliper (Hopkinton, MA). CR8C peptide was
synthesized by Peptide 2.0 Inc. (Chantilly, VA). Other materials were obtained from Sigma-
Aldrich (St. Louis, MO).
2.2 The preparation of 111In-LCP core
111In-LCP core was prepared using a previously described method [15–17] with some
modifications (Supplementary Figure 1). Two water-in-oil microemulsions were prepared:
1) a calcium emulsion: 111InCl3 was premixed with CaCl2 to make a final 50 μL of 500 mM
CaCl2 in 4 mL of cyclohexane oil phase (cyclohexane/Igepal CO-520 = 71/29, v/v), and 2) a
phosphate emulsion: a sufficient amount of 0.05 N NaOH was added to pH 9.0 Na2HPO4 (to
neutralize the extra HCl in the calcium emulsion) to make final 50 μL of 100 mM Na2HPO4
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also in 4 mL of cyclohexane oil phase. DOPA (92.5 μL 34.6 mM in chloroform) as the inner
leaflet lipid was also added in the phosphate emulsion.
After mixing the two microemulsions for 40 min, 8 mL of absolute ethanol was added to the
micro-emulsion to break the microemulsion system. The mixture was stirred for another 30
min. Then, the mixture was centrifuged at 12,500× g for 15 min to collect the 111In -LCP
cores. The cores were washed once with 10 mL absolute ethanol to remove residual
surfactants. Then, the cores were washed with 1.2 mL cyclohexane and mixed with 1.4 mL
absolute ethanol to remove any residual DOPA. Finally, the cores were washed with 2 mL
of absolute ethanol to ensure the removal of cyclohexane. After all washes, the pellets were
dispersed in 250 μL chloroform. The product was centrifuged at 10,000× g for 5min.
Precipitate containing excess salts and aggregates was discarded and the supernatant
containing LCP cores was collected and stored in a glass vial at −20 °C.
2.3 Outer leaflet coating
For outer leaflet coating, 100 μL of 20 mM cholesterol, 100 μL of 20 mM DOPC, and 50 μL
of 20 mM of DSPE-PEG2000 (all in CHCl3) were mixed with the LCP cores in a glass vial.
After complete removal of the CHCl3 by using a stream of nitrogen and vacuum desiccation
for 1 h, the cores were first suspended in 100 μL of pre-warmed absolute alcohol (55 °C)
and then dispersed in total 1 mL pre-warmed aqueous solution containing 5% dextrose.
2.4 Sucrose gradient centrifugation
Sucrose gradient centrifugation assays were performed using NBD-PC, which had a
structure similar to that of DOPC, to mix with DOPC at 1% of the total DOPC to label the
outer leaflet of LCP with fluorescence. The outer leaflet coated LCP was loaded into a tube
containing a sucrose density gradient ranging from 0% to 60% (w/w). After ultra-
centrifugation at 337,000× g for 4 h, excess lipids that were not associated with the LCP
floated to the upper part of the gradient and were separated from the dense LCP which
formed a sharp band above the 60% layer in the gradient.
2.5 Tuning 111In-LCP NP size by adjusting surfactant system
To tune the 111In-LCP core size, a Triton surfactant system (cyclohexane/hexanol/Triton
X-100 = 75/10/15, v/v/v) was mixed with the original Igepal surfactant system
(cyclohexane/Igepal CO-520 = 71/29, v/v). As the portion of the Triton surfactant system
increased, the size of 111In-LCP cores could be enlarged to ~50 nm, making the final larger-
LCP (L-LCP) around 65 nm in diameter.
2.6 Particle size and zeta potential analysis
Particle size and zeta potential of LCP NPs were determined using a Malvern ZetaSizer
Nano series (Westborough, MA). Before measurement, LCP NPs were purified using
sucrose gradient centrifuge method to remove excess lipids. Collected NPs were measured
in water using protocols suggested by the manufacturer.
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2.7 TEM microscopy and sample preparation
LCP cores suspended in chloroform was carefully applied on the formvar/carbon coated
copper 200 mesh grid and allowed to dry for 10 min at room temperature. The volume of
chloroform used should be as small as possible (~1 μL) to prevent dissolution of the
formvar/carbon film. For outer leaflet coated LCP in 5% dextrose solution, 10 μL of the
final LCP solution was applied on the formvar/carbon coated copper 200 mesh grid. The
LCP was allowed to settle on the grid for 10 min. Then the remaining LCP solution was
carefully removed by using a Kimwipes wiper. Another 10 μL of water was used to rinse the
grid to prevent formation of dextrose crystals. After the 10 μL of water was removed
carefully by using Kimwipes wiper, the grid was placed in a dust-free area to allow
complete dryness for at least 30 min before observation using a TEM microscopy (JEOL
100 CS II).
2.8 Determining siRNA entrapment efficiency
To ensure modifications would not compromise the ability to encapsulate siRNA, 35 μg
total double-stranded oligo DNA (as surrogate to siRNA) including 10 μg of 3H-labeled
DNA oligo was added to the calcium emulsion during 111In-LCP preparation. After the LCP
core preparation, oligo entrapment efficiency was determined using liquid scintillation
counting for 3H.
2.9 In vivo SPECT/CT imaging and biodistribution study
All animal work was performed in accordance with and approved by the University of North
Carolina Institutional Animal Care and Use Committee guidelines. Athymic nude (nu/nu)
mice and wild type C57BL/6 mice purchased from National Cancer Institute were used.
SPECT/CT experiments were performed using a GE eXplore speCZT system. A mouse 7-
pinhole collimator was used for high resolution SPECT imaging. Each mouse was injected
through the tail vein with 200 μL of the final 111In-LCP containing ~0.5 mCi of 111In. Mice
were anesthetized with isoflurane and their body temperature was controlled using a water
circuit and warm air. Mice were scanned at 2 h, 4h, and 24 h post IV injection. SPECT/CT
imaging was performed by Biomedical Research Imaging Center at UNC.
Mice were sacrificed and organs/tissues collected at 24 h post injection for biodistribution
studies. Eight lymph nodes, including 2 axillary, 2 brachial, 2 inguinal, and 2 popliteal
lymph nodes were collected. Each organ/tissue sample was counted with a gamma counter
and the reading was corrected for the 111In decay factor during analysis.
2.10 LCP tissue penetrating study by IM injection
111In loaded S- and L-LCP were coated with or without 20% DSPE-PEG2000. Each mouse
received only 10 μL IM injection containing ~5 μCi 111In to the right hind leg muscle to
reduce possible tissue damage. After 3 h or 24 h, mice were sacrificed with major organs
collected for gamma counting. Draining popliteal lymph nodes was collected and four
counter side distal lymph nodes (1 axillary, 1 brachial, 1 inguinal, and 1 popliteal from the
counter side of the IM injection) were also collected for comparison. The gamma reading
was corrected for the 111In decay factor during analysis. Statistical analysis was performed
using a Student’s t-test.
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2.11 Loading Texas-Red oligo into LCP NPs
Double-stranded oligo DNA with Texas-Red labeled on the sense strand was added to the
calcium emulsion during the preparation of the LCP cores. Following the same LCP
preparation protocol, 10 μL IM injection of the Texas-Red oligo loaded S- and L-LCP were
used for the experiment examining the distribution patterns in the draining lymph nodes.
2.12 Study of the distribution of LCP in the draining lymph nodes
Mice were sacrificed 24 h after IM injection of the Texas-Red oligo loaded S- or L-LCP
with the draining popliteal lymph nodes collected. The lymph nodes were fixed in formalin
overnight then put in 30% sucrose solution for another overnight. The lymph nodes were
then mounted in OCT (optimum cutting temperature) compound and snap-frozen by liquid
nitrogen. Frozen sections were cryo-sectioned at a thickness of 20 μm. FITC labeled
antibodies against CD11c or CD11b were diluted to a concentration of 1:500 for
immunostaining. After PBS wash, the slides were mounted with DAPI containing mounting
medium for confocal microscopy observation using a Leica SP2 confocal microscope.
2.13 Establishing 4T1 tumor metastasis model
The luciferase and GFP double-expressed 4T1 murine breast cancer cell line (4T1-luc2-GFP
Bioware® Ultra Green) was used. The tumor model was established by hock injection of
2×105 4T1-Luc2-GFP cells in the right hind leg of 6–8 weeks old female BALB/c mice.
Bioluminescence imaging in a Kodak In-Vivo FX PRO system was performed within 15
min after injection with intraperitoneal luciferin to evaluate tumor metastatic progression
starting around 10 d after hock inoculation. Fluorescent image of the GFP expression of the
dissected lymph nodes were taken using an IVIS Kinetic imaging system.
2.14 Lymph node gene delivery with S-LCP
S-LCP cores were loaded with RFP plasmid and CR8C peptide by mixing 50 μg RFP
plasmid and 50 μg CR8C peptide sequentially with 50 μL of 500 mM CaCl2 solution [18]
with some 111InCl3 for biodistribution evaluation. The core preparation and coating with an
outer leaflet were completed following the same procedure described above. Outer leaflet
lipids of 40% DOPC (or DOTAP) plus 40% cholesterol and 20% DSPE-PEG2000 were used
for coating. Each C57BL/6 mouse received 200 μL of the final S-LCP containing 10 μg of
RFP plasmid and 10 μg of CR8C peptide by IV injection. After 24 h, the mice were
sacrificed and major organs, including 8 lymph nodes, were collected for RFP fluorescence
imaging using a Carestream In-Vivo Imaging System FX Pro and gamma counting.
3 Results
3.1 Preparation of S-LCP and L-LCP
The general procedure for LCP preparation was originally established and optimized for
siRNA encapsulation [15–17]. In order to efficiently formulate 111In into the CaP core,
some major adjustments have been made to this procedure. Since 111In will compete with
calcium for phosphate, the CaCl2 concentration has been reduced from 2.5 M to 500 mM
and the Na2HPO4 concentration (pH 9.0) has been increased from 12.5 mM to 100 mM. For
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the same LCP preparation size, the working microemulsion was thus reduced to 1/8 of the
original volume.
The LCP made with the original Igepal surfactant system (cyclohexane/Igepal CO-520 =
71/29, v/v) was small in size. The CaP core was ~10 nm in diameter and the final LCP NP
coated with the outer leaflet lipids was ~25 nm (Figure 1A), consistent with previous
observations [15, 16]. These small NPs have been termed S-LCP.
By adjusting the microemulsion surfactant system, LCP core size could be tuned between
~10 and ~50 nm in diameter. When mixing the Igepal system with the Triton system at a 1:1
or 1:3 ratio, particles became progressively larger (Figure 1A). When using an Igepal:Triton
ratio at 1:7, the 111In-LCP core was significantly enlarged to ~50 nm. This larger LCP with
a final size, including the outer-leaflet coating, of ~65 nm have been termed L-LCP. Both S-
and L-LCP were coated with dioleoylphosphatidylcholine (DOPC)/Cholesterol/1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-poly(ethylene glycol)2000 (DSPE-
PEG2000) at 2/2/1 molar ratio for the experiments described here unless otherwise specified.
TEM images of the final S- and L-LCP after outer leaflet coating showed that both NPs
were well-dispersed (Figure 1B). The lipid membrane coating of S- and L-LCP was further
characterized by negative staining using uranyl acetate (Figure 1C).
3.2 Characterization of 111In-LCPs
Sucrose-gradient centrifugation was used to purify LCP NPs for characterization described
below. DLS analysis revealed a fairly uniform S-LCP size (~25 nm) with a polydispersity
index (PDI) below 0.3 and a zeta potential of approximately −20 mV. L-LCP, on the other
hand, was around 67 nm in size with a PDI of ~0.4 and a zeta potential around −18 mV
(Table 1). The zeta-potentials of LCP with different outer leaflet coatings are listed in Table
2.
Using a 3H-labeled oligodeoxynucleotide (oligo) and scintillation counting, it was
determined that S-LCP could entrap oligo at an efficiency of ~60%, which was not affected
by the presence of 111In. Oligo entrapment by L-LCP was also unaffected by the presence
of 111In, but only ~30% of the oligo was entrapped (Table 1). 111In entrapment of both S-
and L-LCP was around 30% (Table 1). Inductively coupled plasma mass spectrometry was
used to analyze the LCP core composition. For both S- and L-LCP, the Ca/P ratio was about
1:1, which was different from that of the naturally occurring hydroxyapatite
(Ca10(PO4)6(OH)2, Ca/P = 1.67) (Table 1). These results indicated that the modifications
made for efficient 111In encapsulation did not significantly change any of the properties
listed in Table 1 of the LCP made without 111In.
3.3 Accumulation of S-LCP in the lymph nodes
To study the biodistribution of S-LCP, S-LCP containing ~0.5 mCi 111In was tail vein
injected into both wild-type C57BL/6 and nude mice. SPECT/CT images were taken at 2, 4
and 24 h post injection. Little accumulation occurred in the mononuclear phagocytic system
(MPS) in both the liver and spleen (Figure 2A). The majority of the 111In was found in the
heart and vena cava at 2 h and 4 h post injection, indicating that the S-LCP remain in the
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blood circulation after injection. At 24 h, symmetrical lymph nodes throughout the animal
accumulated significant amounts of the S-LCP (Figure 2B). After SPECT/CT imaging, mice
were sacrificed and their major organs were collected. Gamma counting was performed on
collected organs to determine biodistribution. The collected major lymph nodes had ~70 %
ID/g accumulation of S-LCP. Improved S-LCP core washing and coating with the outer
leaflet contributed to a reduced uptake of the particles by the MPS, ~25% ID/g in both the
liver and spleen (Figure 2C). When mice were injected with L-LCP, higher accumulation in
the MPS (~39% ID/g in the liver and ~289% ID/g in the spleen) and lower lymph node
accumulation (~23% ID/g) were observed (Figure 2C).
3.4 PEGylated S-LCP was more tissue penetrating than L-LCP
To study whether PEGylated S-LCP could penetrate into tissue and lead to lymphatic
accumulation, we designed an intramuscular (IM) injection experiment due to the difficulty
of directly observing particles penetrating into tissues from circulation. PEGylated S-LCP or
L-LCP at 10 μL was IM injected into the muscle of right, hind leg. After 3 h or 24 h, mice
were sacrificed and major organs, including lymph nodes and the injected leg, were
collected for gamma counting. Our hypothesis was that if S-LCP has the ability to achieve
high tissue penetration following local intramuscular injection, they can move more freely in
the tissue, enter into circulation in the blood, and accumulate in the distal lymph nodes.
When the NPs were PEGylated, both S- and L-LCP had an early blood distribution
(observed at 3 h) that could be explained by the mechanical force created by the injection
(Figure 3). In support of our hypothesis, S-LCP exhibited much higher tissue penetration
between 3 and 24 h than L-LCP, as illustrated by decreased retention at the injection site (p
< 0.01, N=3) and a sustained concentration in the circulation. Although there was some
accumulation of S-LCP in the liver, the S-LCP depot at the IM injection site served as a
reservoir to provide a continuous supply of NPs to the blood. Distal lymph nodes were able
to accumulate ~41% ID/g of IM injected S-LCP.
As the initial blood distribution of PEGylated, L-LCP was cleared by the liver, the L-LCP
depot at the IM injection site could not penetrate into the blood to maintain the NP
concentration. The L-LCP depot was limited to the injection site and did not decrease
significantly between 3 and 24 h post-injection (Figure 3). The larger NPs were favored by
the MPS uptake processes; PEGylation in a manner similar to that of the smaller NPs did not
alter this pattern [25, 27]. This phenomenon may explain why PEGylated L-LCP
accumulated in the draining lymph node more than S-LCP. In either case, however, the
effects of PEG protection in reducing their uptake by the MPS (i.e., local macrophages and
dendritic cells) were clear.
3.5 Non-PEGylated L-LCP showed highest accumulation in the draining lymph node
Without PEGylation, both S- and L-LCP had limited mobility (though S-LCP was still more
mobile), trapping more than 80% of the injected dose at the site of injection after 3 h. Since
there was no PEG protection against MPS, the dominant uptake mechanism must be by
phagocytosis of NPs by the nearby macrophages. Rapid and efficient accumulation in the
draining lymph nodes at both 3 and 24 h post-injection were observed. Larger particles
Tseng et al. Page 8






















without PEGylation were preferentially taken up by MPS, as demonstrated by their
accumulation levels of ~3000% ID/g in the draining lymph nodes after 3 h. A list of zeta-
potentials of LCP NPs with different surface coatings can be found in Table 2.
3.6 Different distribution patterns of LCP in the draining lymph node
To study the distribution pattern of LCP in the draining lymph node, S- and L-LCP, both
with 20% PEGylation and loaded with Texas-Red labeled DNA oligo, were used to repeat
the IM injection experiment. After 24 h, the draining lymph nodes were collected and fixed
with formalin for frozen section and observation with confocal microscopy. The results
indicated that labeled S-LCP rarely overlapped with CD11c (dendritic cell marker) or
CD11b (macrophage marker) staining (Figure 4). Labeled L-LCP, on the contrary, mainly
overlapped with CD11c and partially with CD11b.
3.7 PEG coating for S- and L-LCP
To demonstrate the importance of PEGylation to the lymphotropism of S-LCP, an
experiment varying the amount of PEG coating on the S- and L-LCP was conducted. S-LCP
without PEGylation exhibited high accumulation in the liver and spleen, as predicted.
However, there was no difference observed among groups modified with 5, 10, and 20%
PEGylation, indicating that S-LCP did not require a high degree of PEGylation (Figure 5A).
As little as 5% PEG reduced MPS accumulation and increased lymphotropism at levels
comparable to NPs with 20% PEGylation. On the other hand, increased PEGylation on L-
LCP was beneficial, as liver accumulation of the NPs decreased with increasing amounts of
PEGylation (Figure 5B). When coated with 5% PEG, the accumulation of L-LCP became
higher in the spleen compared to NPs without PEG. Increasing the amount of PEG to 10 or
20% can further reduce accumulation of the particles in the liver, but accumulation in the
spleen remains unchanged.
3.8 Imaging lymph node metastasis
A variety of human cancers disseminate via regional lymph node metastasis [28]. The ability
to image sentinel lymph nodes and evaluate the stage of metastasis is highly desirable. To
demonstrate whether S-LCP can be used to detect lymph node metastasis, a 4T1 murine
breast cancer cell line expressing both luciferase and green fluorescent protein (4T1-luc2-
GFP) was used to establish a lymph node metastasis model [29]. After confirming the lymph
node metastasis with luciferase imaging (Figure 6A), the mice were injected through the tail
vein with 111In-S-LCP. SPECT/CT imaging taken at 24 h after injection clearly illustrated
the enlarged, tumor-loaded, metastatic lymph node (Figure 6B).
After SPECT/CT imaging, the mouse was sacrificed for GFP imaging of metastatic cancer
in the lymph nodes (Figure 6C) and organ biodistribution analysis by gamma counting
(Figure 6D). The total accumulated dose in the metastatic lymph nodes was ~1.5 times
higher than in counter-side, popliteal lymph nodes. Accumulation in metastatic lymph nodes
decreased to ~9.1% ID/g, whereas the counter-side, popliteal lymph node remained at 35.4%
ID/g. The overall lymph node accumulation level in this BALB/c, 4T1 model was lower
than what was observed in the C57BL/6 and nude mice. High tumor accumulation (19.1%
ID/g) was observed in the 4T1 tumor.
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3.9 Lymph node gene delivery with S-LCP
The ability of S-LCP NPs to deliver genes to the lymph nodes was demonstrated using a
plasmid containing RFP cDNA. An oligo-arginine peptide flanked by two cysteines
(sequence: CR8C) that significantly enhances the gene-expression level in a study of LCP-
mediated delivery of genes to hepatocytes was also used [18]. S-LCP loaded with the RFP
plasmid, CR8C peptide, and 111In were prepared for this study. The cationic lipid, DOTAP
(1,2-dioleoyl-3-trimethylammonium-propane), was included in this study for outer leaflet
coating to compare with DOPC since DOTAP was known for its higher transfection
efficiency. PEGylation at 20% was still used for both DOTAP and DOPC coated S-LCP
NPs. As demonstrated in Figure 7A, S-LCP-DOTAP had high accumulation in the liver,
but 111In gamma counting indicated much lower accumulation in the lymph nodes. On the
other hand, S-LCP-DOPC showed accumulation that was low in the liver and spleen, but
high in the lymph nodes.
The level of RFP gene expression in liver was also high in mice injected with S-LCP-
DOTAP, which correlated well with the accumulation levels (Figure 7B). For gene
expression in the lymph nodes, although S-LCP-DOPC had a higher accumulation level, the
RFP expression level was lower than that produced by injection with S-LCP-DOTAP
(Figure 7C).
4 Discussion
The invention of the LCP illustrated that a small NP with a lipid bilayer coating could be
created while also maintaining a well-PEGylated surface. LPD (Lipid/Polycation/DNA) NPs
previously developed in our lab, also with a lipid-bilayer coating, had an average size
around 100 nm [30]. Although there are extensive studies of NP biodistribution within this
small size range, they are focused mainly on iron oxide and gold NPs, polymeric micelles,
and quantum dots with different surface protection coatings [19, 27]. There is no literature
that characterizes the in vivo biodistribution behavior of well-PEGylated, lipid-bilayer-
coated NPs in such a small size range. To conduct these studies, an enlarged version of LCP
(L-LCP) was thus developed and the in vivo performance of NPs of both sizes was evaluated
for comparison.
When characterizing NP, it is important to ensure that impurities have been properly
removed after preparation. Since excess lipid may form liposomes or micelles that could
interfere with DLS analysis of LCP, purification using sucrose gradient centrifugation was
necessary to ensure accurate characterization of size and zeta-potential. The same LCP
purification method was also applied while determining 111In loading and DNA oligo
entrapment efficiency.
In the in vivo SPECT/CT imaging study, the reduced accumulation of S-LCP in the MPS is
comparable to many other NPs that are similar in size [19, 25, 27]. However, predominant
systemic accumulation in the lymph nodes is rare after IV injection of NPs. For L-LCP,
there was a small amount of accumulation in the lymph nodes that could be attributed to the
presence of smaller NPs generated during the preparation of L-LCP cores (Figure 1A,
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Supplementary Figure 2). The comparison between S-LCP and L-LCP demonstrated that
small size (~25 nm) is an important factor for lymphotropism
Twenty-four hours after the injection of 111In-S-LCP, over 80% of the total injected 111In
dose was retained in the mouse (Figure 2C), suggesting elimination of S-LCP from the
mouse body was very slow. Thus, the elimination of S-LCP from the blood could be due to
redistribution throughout the body, presumably to the lymphatic system (as shown by the
high accumulation in the carcass and lymph nodes, Fig 2C). This finding is in contrast to
previously mentioned reference NPs [24, 25], which might be excreted after reaching the
liver or kidney. Furthermore, these findings support our hypothesis that S-LCP could
penetrate tissues, enter the lymphatic system, and efficiently accumulate in the lymph nodes
via an atypical lymphatic drainage mechanism due to (1) small size (~25 nm), (2) a well-
PEGylated lipid surface, and (3) a slightly negative surface charge. Lymphatic accumulation
of the nanoparticles also explains the reduction in their concentration in the blood while
maintaining minimal excretion and accumulation in other major organs (liver, spleen, etc.).
Since S-LCP was more able to penetrate tissues and was taken up minimally by the MPS
due to their smaller size, one reasonable prediction is that the majority of S-LCP were
drained into the lymph nodes as individual particles. On the other hand, the bulk of the
accumulation of L-LCP in the lymph nodes after IM injection is most likely MPS mediated
[31]. As shown in Figure 4, labeled S-LCP rarely overlapped with CD11c (dendritic cell
marker) or CD11b (macrophage marker) staining. Since dendritic cells and macrophages
were the two major phagocytic cells in the lymph nodes, our results suggested that S-LCP
remained as individual particles in the lymph nodes. In the case of L-LCP, Texas-Red
fluorescence overlapped mostly with CD11c and only partially with CD11b. Combined with
the observation that IV injected L-LCP had low accumulation in the lymph nodes, this
suggests that after IM injection, L-LCP accumulation in the draining lymph nodes was
mainly mediated by MPS uptake at the injection site, after which the MPS cells migrated to
the draining lymph nodes.
How the degree of PEGylation affects LCP lymphotropism is also interesting.
Geometrically, NPs will have increased curvature as they become smaller in size. In order to
provide a comparable degree of surface protection, a higher degree of PEGylation would be
required by an S-LCP (~25 nm) than an L-LCP (~67 nm). However, smaller NPs might
inherently possess a stealth property that allows them to avoid uptake by the MPS and thus
require less PEGylation. The results in Figure 5 supported this hypothesis. It also suggested
that PEGylation could significantly reduce uptake by the MPS in the liver, but not the
spleen. Only when the NP size was reduced, could we achieve significant reduction in the
amount of accumulation of the NPs in the spleen. This accumulation pattern also holds true
for many other types of NPs in addition to the one described here [25, 27].
Even when PEGylated at 20% PEG, L-LCP exhibited much lower accumulation in the
lymph nodes compared to S-LCP, (~21% vs. ~70% ID/g, respectively). The lower degree of
accumulation in the lymph nodes could be explained by the population of smaller particles
that was generated as a by-product during the process to create the L-LCP cores (Figure
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1A). Alternatively, NPs could be carried by MPS cells in the periphery and migrated into the
lymph nodes [31].
An uneven distribution of 111In in the metastatic lymph node (Figure 6B) was most likely
due to the presence of the tumor mass that excluded lymphatic fluid, an observation that was
also reported in other clinical studies using Feridex® [20, 32].
Due to enlargement of the metastatic lymph nodes caused by tumor growth and
inflammation, the accumulation level was reduced to ~9.1% ID/g as a result of increased
organ weight of the lymph nodes, whereas the counter-side, popliteal lymph node was
measured at 35.4% ID/g (Figure 6D). However, the accumulated 111In signal was sufficient
for imaging, leading to the observation of the uneven distribution pattern (Figure 6B) [32].
The overall lymph node accumulation in this BALB/c, 4T1 model was lower than what was
observed in the C57BL/6 and nude mice. The decrease could be attributed to higher MPS
function induced by the 4T1 tumor, as indicated by a significantly larger spleen in this
model (data not shown). However, the 4T1 tumor achieved high tumor accumulation (19.1%
ID/g), which might also contribute to the overall lower accumulation in the lymph nodes of
this model. This work demonstrated the feasibility of using 111In-S-LCP to image metastatic
lymph nodes via intravenous injection.
The high accumulation and RFP expression level with S-LCP-DOTAP in the liver (Figure
7A) was due to efficient uptake by hepatocytes but not Kupffer cells (as been discussed by
Liu et al, manuscript in submission). For the observation that S-LCP-DOTAP has lower
accumulation but higher RFP expression in the lymph node (Figure 7B), there are two
possible explanations. The first depends on the high transfection efficiency of positively-
charged DOTAP, due to its ability to facilitate endosome escape. The higher expression of
RFP despite the lower delivered dose suggests that S-LCP-DOTAP exhibited a higher gene
expression activity than S-LCP-DOPC. Alternatively, positively charged DOTAP could also
aid in the cellular uptake process after PEG shedding [33–35]. Cellular uptake of S-LCP-
DOPC in the lymph nodes might be limited (Figure 4). If cellular uptake was low, the
bioavailability of the RFP plasmid is likely to be low as well.
Figure 3 suggests that local injection of non-PEGylated larger particles, such as non-
PEGylated L-LCP, would be sufficient for vaccination or sentinel lymph node mapping
since systemic accumulation and delivery to the lymph node is not required and local
injection of larger particles actually achieved higher levels of local accumulation [36–42].
NPs for vaccination or sentinel lymph node mapping are readily achievable since they do
not require a high degree of PEGylation. There is also a fairly broad, acceptable range of
particle size. On the other hand, the more sophisticated S-LCP-DOPC would be more
effective in achieving systemic lymphatic drug delivery, due to highly specific accumulation
in the lymph nodes after IV injection. This characteristic would be desirable in the treatment
of diseases such as HIV infection. The HIV virus in the lymph nodes is difficult to treat due
at least in part to the limited ability of anti-HIV drugs to access the lymph nodes [43].
Strategies such as formulating anti-HIV drugs into lipid NPs to enhance the lymph-node-
specific accumulation of anti-HIV drugs have been reported [44–47]. However, these
formulations were administered by subcutaneous injection and could only enhance the
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concentration of drugs in regional lymph nodes. The lymphotropism of LCP, along with the
ability of some anti-viral and anti-tumor nucleoside analogue drugs to be entrapped by a
similar strategy [48], supports the use of LCP for delivery of nucleoside-analog drugs in the
treatment of metastatic cancer and HIV infection in the lymph nodes.
Targeting ligands could be incorporated to enhance cell-type specific uptake. For instance,
CD4-targeting peptides that could enhance cellular uptake by CD4-HIV host cells could be
grafted onto S-LCP-DOPC [49]. With the lymphotropism of S-LCP-DOPC, systemic
eradication of HIV infection in the lymph nodes might be possible. Future directions to
improve the lymphatic drug delivery efficiency of LCP would include: 1) adding an
endosome escape enhancer to the S-LCP-DOPC to boost gene expression activity, and 2)
adding targeting ligands to enhance cell-type specific uptake in the lymph nodes. If
successful, S-LCP-DOPC could serve as a drug delivery formulation that is highly specific
to the lymph nodes.
5 Conclusion
We have demonstrated successful loading of 111In into LCP NPs. A rare lymphotropic
property of S-LCP was studied. The results supported the hypotheses that S-LCP was able to
penetrate into tissues, travel within the lymphatic system, and accumulate in the lymph
nodes as individual NP due to 1) small size, 2) a well-PEGylated lipid surface, and 3) a
slightly negative surface charge. With SPECT/CT, IV injected, lymphotropic S-LCP could
be useful for imaging of systemic lymph node metastasis. Systemic gene/drug delivery to
the lymph nodes has been demonstrated with RFP cDNA expression in lymph nodes. These
results suggest the potential use of IV injected S-LCP formulation as a theranostic delivery
system to the lymphatic system.
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Ksp solubility product constant
MPS mononuclear phagocytic system
ID/g injected dose per gram tissue
SPECT single photon emission computer tomography
Tseng et al. Page 13






















PET positron emission tomography










DLS dynamic light scattering
PDI polydispersity index
PK pharmacokinetics
GFP green fluorescent protein
RFP red fluorescent protein
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A) TEM images of 111In -LCP core made with different Igepal system to Triton system mixing ratio. S- and L-LCP were made
by Igepal system to Triton system ratio 1:0 and 1:7, respectively. B) TEM images of S- and L-LCP after outer leaflet coating. C)
Negative staining of S- and L-LCP to show the lipid coating.
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A) SPECT/CT images of nude mouse taken at 2 h and 4 h post IV injection of S-LCP containing ~0.5 mCi 111In. Strong 111In
signals were mainly observed in the heart and vena cava (red arrow). B) SPECT/CT images taken at 24 h post IV injection. Four
different horizontal sections were included to show that symmetrical lymph nodes (yellow arrows) throughout the body
accumulated significant amount of S-LCP. C) Biodistribution results determined by organ dissection and gamma counting. S-
LCP in nude mice and C57BL/6 mice; L-LCP in C57BL/6 mice were shown. Note that only eight major lymph nodes were
collected for counting. (N=3 for each group)
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Biodistribution comparison after IM injection of 111In loaded S- and L-LCP coated with or without 20% DSPE-PEG2000. Mice
were sacrificed at 3 h or 24 h post IM injection.
Tseng et al. Page 19























S-LCP was largely not co-localized with phagocytic cells in the draining lymph node observed with confocal microscopy. LCP
was labeled with Texas-red-labeled oligo and phagocytic cells (CD11c for dendritic cells and CD11b for macrophages) were
labeled with green. Nuclei were stained with DAPI in blue. Left panels are for S- and right panels are for L-LCP, respectively.
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Effect of PEGylation on the biodistribution of S-LCP (A) and L-LCP (B). Results with different degree of PEGylation at 0%,
5%, 10%, and 20% were shown.
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Imaging lymph node metastasis on a 4T1 breast cancer model. A) Bioluminescence image of two BALB/c mice was taken 10 d
after hock inoculation. B) SPECT/CT images taken at 24 h post IV injection of 111In-S-LCP. Two horizontal and two vertical
sections were shown. The enlarged and tumor loaded sentinel, popliteal lymph node could be directly compared with the
counter-side, popliteal lymph node. C) GFP fluorescent images of the metastatic 4T1-luc2-GFP cancer cells in the lymph nodes.
Eight lymph nodes (from top to bottom: 2 axillary, 2 brachial, 2 inguinal, and 2 popliteal) from both side of one mouse were
shown. D) S-LCP biodistribution 28 h post injection at liver, spleen, 4T1 tumor, and various lymph nodes by gamma counting.
(N=3)
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A) Biodistributions of S-LCP-DOPC and S-LCP-DOTAP with 20% PEGylation at 24 h post IV injection determined by gamma
counting. RFP gene expression at the major organs (B) and the eight lymph nodes (C) were shown by RFP fluorescent imaging.
Tseng et al. Page 23
































































































































































































































































































































































































Tseng et al. Page 25
Table 2
Zeta-potentials of LCP with different outer leaflet coatings
DOPC/Cholesterol + 20% DSPE-PEG DOPC/Cholesterol + 0% DSPE-PEG DOTAP/Cholesterol + 20% DSPE-PEG
S-LCP −19.9 ± 4.1 mV −3.8 ± 2.1 mV 21.3 ± 2.1 mV
L-LCP −18.0 ± 2.0 mV −3.3 ± 1.8 mV N/A
Measured by dynamic light scattering (N=3)
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